Med-IQ
IBS-D Treatment: Incorporating Effective Strategies in a New Era
E-publication E-publication

IBS-D Treatment: Incorporating Effective Strategies in a New Era


Presented by the AGA Institute and Med-IQ.

AGA InstituteMed-IQ

Time to Complete:
30 minutes
Released:
8/16/16
Expires:
8/15/17

Maximum Credits:

0.5 AMA PRA Category 1 Credit(s)

E-publication E-publication
Time to Complete:
30 minutes

Released:
8/16/16

Expires:
8/15/17

Maximum Credits:
0.5 AMA PRA Category 1 Credit(s)
Share on:
E-publication E-publication

Share on:


Time to Complete:
30 minutes
Released:
8/16/16
Expires:
8/15/17


Maximum Credits:
0.5 AMA PRA Category 1 Credit(s)


Overview: This CME-certified publication reviews treatment options for patients with irritable bowel syndrome with diarrhea (IBS-D) and focuses on the practical aspects of incorporating newly approved agents into clinical practice. Key topics to be discussed include the diagnosis of IBS, the safety and efficacy of recently approved pharmacologic agents, and practical considerations for optimizing treatment. This publication also incorporates faculty insights from a symposium that took place at Digestive Disease Week 2016 and includes a case vignette to highlight the real-world applications of using recently approved pharmacologic agents in everyday practice.

Faculty

William D. Chey, MD, AGAF, FACG, FACP, RFF

Timothy T. Nostrant Professor of Gastroenterology & Nutrition Sciences

Director, GI Physiology Laboratory

Medical Director, Michigan Bowel Control Program

Director, Digestive Disorders Nutrition & Lifestyle Program

Division of Gastroenterology

University of Michigan Health System

Ann Arbor, MI

Anthony J. Lembo, MD, AGAF

Associate Professor of Medicine

Harvard Medical School

Beth Israel Deaconess Medical Center

Boston, MA


Disclosure Policy

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

William D. Chey, MD, AGAF, FACG, FACP, RFF
Consulting fees/advisory boards: Actavis, Ardelyx, AstraZeneca, IM Health, Ironwood Pharmaceuticals, Inc., Nestle Health Science, Prometheus Laboratories Inc., QOL Medical, LLC, SK Biopharmaceuticals Co., Ltd., Takeda Pharmaceuticals North America, Inc., Sucampo Pharmaceuticals, Inc.
Contracted research: IM Health, Ironwood Pharmaceuticals, Inc., Nestle Health Science, Prometheus Laboratories Inc., Vibrant Pharma Inc.
 
Anthony J. Lembo, MD, AGAF
Consulting fees/advisory boards: Alkermes, Allergan, Inc., Ironwood Pharmaceuticals, Inc., Prometheus Laboratories Inc., Salix Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc. 

The peer reviewers and activity planners have no financial relationships to disclose.


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by an educational grant from Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.